Publications by authors named "Lyudmila Emelyanova"
Antibody-dependent enhancement (ADE) has been shown previously for SARS-CoV-1, MERS-CoV, and SARS-CoV-2 infection in vitro. In this study, the first monoclonal antibody (mAb) that causes ADE in a SARS-CoV-2 in vivo model was identified. mAb RS2 against the SARS-CoV-2 S-protein was developed using hybridoma technology.
View Article and Find Full Text PDF, formerly tick-borne encephalitis virus (TBEV), belongs to the genus. TBEV is transmitted by tick bites and infection with TBEV can lead to serious disorders of the central nervous system. In this study, a new protective monoclonal mouse antibody (mAb) FVN-32, with high binding activity to glycoprotein E of TBEV, was selected and examined in post exposure prophylaxis in a mouse model of TBEV infection.
View Article and Find Full Text PDFVaccinia virus (VACV) is a promising oncolytic agent because it exhibits many characteristic features of an oncolytic virus. However, its effectiveness is limited by the strong antiviral immune response induced by this virus. One possible approach to overcome this limitation is to develop deimmunized recombinant VACV.
View Article and Find Full Text PDFArticle Synopsis
- The flaviviral NS1 glycoprotein is crucial in tick-borne encephalitis (TBE) pathology and could serve as a biomarker for early diagnosis and a target for therapy.
- Eukaryotic expression systems are typically used to produce NS1, but attempts to express it in Escherichia coli were largely unsuccessful due to solubility and folding issues.
- This study successfully produced soluble Trx-fused TBEV NS1 in E. coli by modifying cultivation conditions, and both soluble and refolded proteins exhibited immunological properties similar to native NS1, confirmed through various analysis methods.